Turkish Thoracic Journal
Review

Managing Lung Cancer during Coronavirus Disease 2019 Pandemic

1.

Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Turk Thorac J 2021; 22: 163-168
DOI: 10.5152/TurkThoracJ.2021.20110
Read: 75 Downloads: 17 Published: 06 April 2021

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as a pandemic by the World Health Organization. As this disease continues to spread worldwide, it has posed enormous challenges on the healthcare of several diseases, especially cancer, because hospital facilities have invested health resources for patients with COVID-19. Indeed, patients with lung cancer are particularly vulnerable because of their poor baseline lung function and cancer-related treatment. In addition, once infected, they are at an increased risk of pulmonary complications from COVID-19. Oncologists are thus facing a challenge as how to balance the treatment plans to control the disease while protecting the patients with lung cancer from COVID-19. In fact, it is crucial to provide individualized treatment recommendations to limit the risks during these difficult times. This review highlights the key challenges that oncologists face when diagnosing COVID-19 among patients with lung cancer and examines the current recommendations from available literature, clinical expertise, and expert opinions regarding managing lung cancer in the era of COVID-19. It also explores the treatment approach recommended for patients with lung cancer while avoiding putting them at excessive risk of contracting COVID-19 infection.

Cite this article as: Khalifeh YI, Tfayli AH. Managing Lung Cancer during Coronavirus Disease 2019 Pandemic. Turk Thorac J 2021; 22(2): 163-8.

Files
EISSN 2149-2530